With three of the four top neuromodulation companies reporting high-single-digit (HSD) growth in Q123, manufacturers are keeping their fingers crossed that market recovery is well underway. The impact of COVID has lessened significantly and several manufacturers reported that near-term improvement in healthcare staffing levels and post-COVID demand helped drive strong underlying procedure volumes in Q123. Competitors are also seeing gains on new and differentiated product offerings and expanded indications.
2 min read
Fingers Crossed for a Market Recovery: Q123 Neuromodulation Market Recap
By Anne Staylor on 7/28/23 9:23 AM
2 min read
The Future of Interventional Pain Management and Peripheral Nerve Stimulation
By Anne Staylor on 7/17/23 3:13 PM
SmartTRAK’s survey of interventional pain physicians reveals valuable insights into current and future trends in interventional pain management and peripheral nerve stimulation (PNS)
SmartTRAK recently conducted a survey of 30 interventional pain physicians, including 18 doctors who perform PNS, to gain insight into the current state of interventional pain management and identify future trends in the field. This includes physician use of SCS, DRG Stimulation, short- and long-term PNS, RFA, TDD, Regenerative Medicine injections and MIS spine procedures, with an emphasis on PNS companies and technologies.
This comprehensive study sheds light on procedure trends, preferred treatment approaches, physicians' perspectives on PNS and more!
Key questions include:
- What interventional pain procedures are expected to grow the most in the next 12-24 months?
- What minimally invasive spine procedures do physicians think will increase the most in the next few years?
- What are expected procedure volumes for Regenerative Medicine injections?
- What are the most preferred treatment approaches for different chronic pain conditions?
- What are physicians' impressions of the different PNS technologies/brands?
- What are the top targets for PNS and what's driving and limiting physician adoption of PNS?
- What technology improvements do physicians want to see in PNS devices?
Click the button below if you are interested in purchasing SmartTRAK’s Interventional Pain Management and Peripheral Nerve Stimulation Survey. Be The Expert with the latest insights and trends in the field and equip yourself with valuable knowledge. Click Now!
4 min read
What's New and What's Next at Abbott Neuromodulation
By Anne Staylor on 4/18/23 9:30 AM
Rebecca Wilkins, DVP R&D Neuromodulation for Abbott, discusses the Eterna SCS, strategies for penetrating the market for PDN, the latest initiatives for DBS and DRG and what’s next for the Company in an interview with SmartTRAK.
Rebecca Wilkins, Divisional Vice President, Research and Development, Neuromodulation at Abbott, discusses Eterna, the Company’s newest rechargeable spinal cord stimulator, strategies for penetrating the market for painful diabetic neuropathy (PDN), the latest initiatives in deep brain stimulation and what’s next in terms of research and innovation an interview with SmartTRAK.
To find out more, listen to the interview by clicking on the following video (19:41 min). A link to download a complete transcript of the interview is also provided below...just click Continue Reading.
2 min read
Navigating Choppy Waters: Q422 Neuromodulation Market Recap
By Anne Staylor on 3/20/23 10:06 AM
While the macro environment is improving, some neuromodulation companies and segments navigated choppy waters in Q422
- Complete Q422 Neuromodulation Market Overview
- SmartTRAK's Expert Market Analysis and Insights
- All Company News, Revenues, Data, Charts and Shares
- Spinal Cord Stimulation Sees Growth Exiting 2022
- Macro Environment Improving
- Innovation, Expanding Indications Driving Growth
- Potential Payer Headwinds
- DBS Slows on Replacement Headwinds, Share Shifts
- Q422 Clinical/Regulatory Highlights
2 min read
Saluda Medical: Changing the Game in Spinal Cord Stimulation
By Anne Staylor on 3/14/23 9:54 AM
Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK
With the US launch of the Evoke System, Saluda Medical is changing the game in spinal cord stimulation (SCS). At the North American Neuromodulation Society (NANS) Annual meeting in Las Vegas in January, researchers presented impressive 36-month data from the Company’s Evoke Study and the Company was showcasing its Evoke System for the first time on the NANS exhibit hall floor. As the first commercially available closed-loop SCS system using evoked compound action potentials (ECAPs), Evoke is unlike anything on the market. The technology automatically adjusts stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. The Company received FDA PMA for Evoke in February 2022 and announced a limited US commercial release in December 2022, calling it the first and only ‘SmartSCS” in the US.
Saluda Medical President and CEO Jim Schuermann discusses bringing Evoke System to market, the Company’s US launch and commercialization plans, the newest generation of Evoke, his vision for the future and Evoke’s potential impact on the market in an interview with SmartTRAK. Click the button below to download and read a complete transcript of the interview.
3 min read
Spotlight on Medtronic Neuromodulation: NANS 2023
By Anne Staylor on 2/10/23 11:40 AM
Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodulation in an interview with SmartTRAK at NANS 2023
Nnamdi Njoku, Medtronic’s Senior Vice President and President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss what’s new for Medtronic Neuromodulation, expected market growth in 2023 and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS) in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 26th Annual Meeting held January 12-15, 2023 in Las Vegas, Nevada.
To find out more about the Company’s latest innovations, expanding indications and what’s next for Medtronic Neuromodulation, click on the following video recorded live at NANS 2023. (27:57 minutes.) Specific interview topics by time code are outlined below. A link to download a complete transcript of the interview is also provided below.
2 min read
Neuromodulation Trends: SmartTRAK at NANS 2023
By Thomas Wallick on 1/10/23 9:00 AM
SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging trends at NANS 2023
Anne Staylor, SmartTRAK's Executive Editor VP & GM, Neuro Therapies, will again be attending and reporting on the North American Neuromodulation Society Annual Meeting (NANS), this year being held in Las Vegas, January 12-15th. If you would like to meet with Anne while at NANS, just click here.
Last year, Anne published a prescient article from the NANS 25th Annual Meeting titled "Neuromodulation Trends in 2022 and Beyond" in which she identified key trends from the meeting in Orlando and provided an outlook of what’s on the horizon for neuromodulation. This included trends in research and technology that will help shape the markets for spinal cord stimulation (SCS), deep brain stimulation (DBS) and peripheral nerve stimulation (PNS), advances in closed-loop therapies, improving care through digital solutions and driving growth through expanding indications.
To download and read the complete "Neuromodulation Trends in 2022 and Beyond" article, just click here.
2 min read
Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap
By Anne Staylor on 12/29/22 9:30 AM
Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds
Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.
Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are: